Sanofi Reports P-II (ElevAATe) Trial Data on Efdoralprin alfa for Alpha-1 Antitrypsin Deficiency (AATD)-Related Emphysema

Shots: Sanofi has reported the P-II (ElevAATe) study data assessing efdoralprin alfa (Q3W or Q4W) vs SoC plasma-derived augmentation therapy (pdAAT; QW) in 97 pts with AATD-related emphysema Efdoralprin alfa achieved a mean increase in fAAT trough levels of 24.1μM (Q3W) & 16.8μM (Q4W) vs 7.6μM at Wk. 32, with Q3W meeting the 1EP, while…

ByRidhi Rastogi3 days ago

NEWS

Regeneron and Tessera Therapeutics Enter ~$275M Collaboration to Advance TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD)

Shots: Regeneron has entered into a global collaboration with Tessera Therapeutics to develop & commercialize TSRA-196 as a one-time gene editing treatment of AATD As per the deal, Tessera & Regeneron will equally share global development costs & potential future profits for TSRA-196. Tessera will receive $150M in upfront & equity investment plus $125M in near…

ByRidhi RastogiDecember 2, 2025

Sanofi Reports P-II (ElevAATe) Trial Data on Efdoralprin alfa for Alpha-1 Antitrypsin Deficiency (AATD)-Related Emphysema

Regeneron and Tessera Therapeutics Enter ~$275M Collaboration to Advance TSRA-196 for Alpha-1 Antitrypsin Deficiency (AATD)

Contact US

FOLLOW US